Michelle Lee, the director of the United States Patent and Trademark Office, has resigned, IP Watchdog reports.
The University of California is appealing the recent CRISPR/Cas9 patent decision.
The Broad Institute has a shot to end the dispute by early 2017 but the more likely outcome is that the parties will argue over whether to fracture the CRISPR IP estate.
Continuing litigation that began in 2012, Illumina alleges that Qiagen's GeneReader infringes on a patent it holds related to sequencing-by-synthesis technology.
The parties involved in the CRISPR patent fight recently held a conference call, Stat News reports.
A patent examiner has issued an Initial Interference Memo in the CRISPR patent fight, possibly leading to an interference proceeding, according to the Law and Biosciences Blog.
The report, which takes a look at patent issues as it relates to confirmatory genetic tests, acknowledged that federal legislation has dramatically changed the landscape in recent years.
Researchers report in PLOS One on their examination of the percentage of women represented on patent filings.
Title: Methods and Means for Producing Efficient Silencing Construct Using Recombinatorial Cloning
Patent Number: 8,877,435
Title: Construction of Protein-responsive shRNA/RNAi Control System Using RNP Motif
Patent Number: 8,871,437
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.